FDA Withdraws from Global Harmonization Working Party
On November 27, the FDA announced its withdrawal as a member of the Global Harmonization Working Party (GHWP), which the agency joined in December 2021. The FDA stated that it will continue its outreach to global partners and its efforts to ensure alignment of medical device international harmonization by primarily working with the International Medical Device Regulators Forum (IMDRF).
The FDA cited the following benefits of working with IMDRF:
- The FDA, and other international regulators, are a part of the decision-making process.
- Decisions are made by consensus of all regulators on the management committee.
- Development of documents is driven by regulators.
- There is a clear and consistent public consultation process to allow for stakeholder engagement.
On September 18, 2023, the FDA issued the draft Center for Devices and Radiological Health International Harmonization Strategic Plan. This plan includes strategies to directly encourage harmonization, convergence and reliance among medical device regulatory authorities, as applicable, and highlights CDRH’s current work with international stakeholders.
Related Articles
-
The MedTech Regulatory Intelligence Virtual Summit offers informational sessions and panel discussion on the current focus of FDA CDRH, European and Asian Markets, and Strategies to Streamline Your Regulatory Operations, delivered over three days on November 13-15. Join from your…
-
The committee will advise the Commissioner of Food and Drugs on issues related to Digital Health Technologies (DHTs), and FDA policies and regulations about these technologies, providing relevant expertise and perspective to improve the FDA’s understanding of the benefits, risks…
-
The CERSI program was established to foster robust and innovative approaches to advance regulatory science through collaborative interactions with FDA scientific experts.
-
The guidance provides a framework that manufacturers can use to show that physics-based or mechanistic computational models used to support regulatory submissions are credible.
